ReCode Therapeutics

ReCode Shehnaaz Suliman Annalee Armstrong

Biotech

ReCode CEO Shehnaaz Suliman eyes second half IPO opportunity

As green shoots slowly push from the biotech markets, ReCode CEO Shehnaaz Suliman, M.D., is watching closely, biding her time for a potential H2 IPO.

Annalee Armstrong Jan 17, 2024 10:31am

A lightbulb in a yellow bowl of pennis

Bioluminescence enters biotech venture spotlight with $477M

Nov 1, 2023 7:00am

Fierce Biotech's 2022 Fierce 15

Sep 12, 2022 3:00am

abortion uterus pregnancy pills

Women in biotech see Roe v. Wade ruling as a call to action

Jul 11, 2022 8:00am

genetic medicine Mrna dna

ReCode breaks the mold with $120M financing, Big Pharma backing

Jun 29, 2022 6:00am

Parachute

Galapagos aims to announce new CEO within weeks—Chutes & Ladders

Jan 14, 2022 9:30am